Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Esarin Gel
- Development stage
- Phase 4
- Lead developer
- Sun Pharmaceutical Industries
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
**Esarin Gel** is a topical fixed-dose combination marketed in Taiwan for supportive improvement of chronic venous insufficiency and relief of post-traumatic pain. Each gram contains diethylamine salicylate 50 mg, escin 10 mg, and heparinoid 10 mg, specified as sodium polyanhydromannuronic acid sulfate. The heparinoid component supports local antithrombin-mediated anticoagulant activity, escin is a venotonic and capillary-permeability-modulating triterpene saponin, and diethylamine salicylate provides local salicylate-mediated analgesic and anti-inflammatory effects. A completed open-label Phase 4 study evaluated twice-daily Esarin Gel for 28 days in chronic venous insufficiency, varicose veins, and superficial vein thrombophlebitis. ([web-reg-server.803.org.tw](https://web-reg-server.803.org.tw/PhC/PharmaBooks/Keyword_Detail/xhzhegXOzgaK0br_hW5j0rHD3cByTmL3GhCIXv9cbXp7fkfkdobKplfGzlUHabwx))
- Brand names
- Esarin Gel
- Other names
- diethylamine salicylate + escin + sodium polyanhydromannuronic acid sulfate礙沙凝膠
02
Targets
ATIII (Antithrombin III)HYAL (Hyaluronidase family (HYAL))PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Esarin Gel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Esarin Gel.